Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katia Todoerti

Showing results (51-60 of 102) with videos related to

Pageof 11
Sort By:
Oncotarget|October 27, 2015
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patientsEnrica Calura, Andrea Bisognin, Martina Manzoni, et al.
Cancer Letters|February 17, 2020
COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell deathTiziana Di Marco, Francesca Bianchi, Lucia Sfondrini, et al.
Nucleic Acids Research|May 1, 2015
The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNASimona Segalla, Silvia Pivetti, Katia Todoerti, et al.
Genes, Chromosomes & Cancer|December 12, 2013
Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell lineDonata Verdelli, Lucia Nobili, Katia Todoerti, et al.
Tumori|July 9, 2025
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridizationDaniele Lorenzini, Rebecca Salvatori, Chiara Costanza Volpi, et al.
Cancer Letters|September 28, 2017
Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cellsMaria Chiara Anania, Elena Cetti, Daniele Lecis, et al.
Ebiomedicine|February 10, 2019
A GBM-like V-ATPase signature directs cell-cell tumor signaling and reprogramming via large oncosomesIrene Bertolini, Andrea Terrasi, Cristina Martelli, et al.
Drug Design, Development and Therapy|July 15, 2021
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of MyelomaFortunato Morabito, Giovanni Tripepi, Enrica Antonia Martino, et al.
Oncotarget|October 3, 2015
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screeningMaria Anania, Fabio Gasparri, Elena Cetti, et al.
European Journal of Haematology|April 23, 2010
The clinical and biological features of a series of immunophenotypic variant of B-CLLLilla Cro, Andrea Ferrario, Marta Lionetti, et al.
Pageof 11

Showing results (51-60 of 102) with videos related to

Sort By:
Pageof 11
Oncotarget|October 27, 2015
Disentangling the microRNA regulatory milieu in multiple myeloma: integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patientsEnrica Calura, Andrea Bisognin, Martina Manzoni, et al.
Cancer Letters|February 17, 2020
COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell deathTiziana Di Marco, Francesca Bianchi, Lucia Sfondrini, et al.
Nucleic Acids Research|May 1, 2015
The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNASimona Segalla, Silvia Pivetti, Katia Todoerti, et al.
Genes, Chromosomes & Cancer|December 12, 2013
Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell lineDonata Verdelli, Lucia Nobili, Katia Todoerti, et al.
Tumori|July 9, 2025
Validating HER2 copy number variation assessment by NGS: A comparative analysis with immunohistochemistry and in situ hybridizationDaniele Lorenzini, Rebecca Salvatori, Chiara Costanza Volpi, et al.
Cancer Letters|September 28, 2017
Targeting COPZ1 non-oncogene addiction counteracts the viability of thyroid tumor cellsMaria Chiara Anania, Elena Cetti, Daniele Lecis, et al.
Ebiomedicine|February 10, 2019
A GBM-like V-ATPase signature directs cell-cell tumor signaling and reprogramming via large oncosomesIrene Bertolini, Andrea Terrasi, Cristina Martelli, et al.
Drug Design, Development and Therapy|July 15, 2021
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of MyelomaFortunato Morabito, Giovanni Tripepi, Enrica Antonia Martino, et al.
Oncotarget|October 3, 2015
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screeningMaria Anania, Fabio Gasparri, Elena Cetti, et al.
European Journal of Haematology|April 23, 2010
The clinical and biological features of a series of immunophenotypic variant of B-CLLLilla Cro, Andrea Ferrario, Marta Lionetti, et al.
Pageof 11